Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Medicine
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Medicine
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

JCI Insight Editorial Board
potential first-tier conflicts of interest

Updated September 1, 2024

Go to JCI Insight's conflict-of-interest policy

Alnylam (SP Monga)

Antlera (SP Monga)

AstraZeneca (ME Snyder)

Bayer (TL Suber, SY Chan)

Bristol Myers Squibb (O Eickelberg)

Coloma Therapeutics (T Finkel)

Corcept Therapeutics (PK Fazeli)

Crinetics (PK Fazeli)

ED Soreno (HD Skinner)

Eli Lilly (EE Kershaw)

Fauna Bio (O Eickelberg)

Generian Pharmaceuticals (T Finkel)

Haemonetics (MD Neal)

Haima Therapeutics (MD Neal)

Immunetrics (TR Billiar)

Instrumentation Laboratories (MD Neal)

Pfizer (A Morris, EE Kershaw)

Regeneron (EE Kershaw)

Santa Ana Bio (A Ray)

Synhale Therapeutics (SY Chan)

Takeda (MD Neal)

United Therapeutics (SY Chan)

WoodNext Foundation (SY Chan)

Advertisement

Copyright © 2024 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts